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Background: Although obstetrician/gynecologists (OB/GYNs) play an important role in sickle cell disease (SCD)
screening and patient care, there is little information on knowledge of SCD or sickle cell trait (SCT) or related
practices in this provider group. Our objective was to assess SCD screening and prenatal management practices
among OB/GYNs.
Methods: Twelve hundred Fellows and Junior Fellows of the American College of Obstetricians and Gynecologists
(the College)a were invited to complete a mailed survey, of which half (n = 600) belonged to the Collaborative
Ambulatory Research Network.b Participants answered questions regarding appropriate target patient groups for
prenatal SCD screening, folic acid requirements, practice behaviors and adequacy of their medical school and
residency training.
Results: A total of 338 CARN members (56.3%) and 165 non-CARN members (27.5%) returned a survey. Of the 503
responders, 382 provided obstetric services and were included in the analyses. Forty percent of these respondents
(n = 153) reported seeing at least 1 patient with SCD in the last year. Of these, 97.4% reported regularly screening
people of African descent for SCD or SCT, whereas 52.9% reported regularly screening people of Mediterranean
descent and 30.1% reported regularly screening people of Asian descent. Only 56.2% knew the correct recommended
daily dose of folic acid for pregnant women with SCD. The proportion of respondents that rated training on SCD
screening, assessment and treatment as barely adequate or inadequate ranged from 19.7% to 39.3%.
Conclusions: The practice of many OB/GYNs who care for patients with SCD are not consistent with the College
Practice Guidelines on the screening of certain target groups and on folic acid supplementation. There may be an
opportunity to improve this knowledge gap through enhanced medical education.
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Sickle cell disease (SCD) affects 80,000 to 100,000
people in the United States; approximately 3 million
people are carriers of sickle cell trait (SCT) [1,2]. Sickle
cell is a complex disease for which successful manage-
ment requires the coordination of care and health ser-
vices from a multi-disciplinary team [3]. While great
strides have been made in the pediatric arena, advances
in SCD management have extended the lifespan of those
affected and have increased the need for coordinated
adult care [4,5]. A study by Quinn et al. demonstrated* Correspondence: JSchulkin@acog.org
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unless otherwise stated.that the risk of mortality in patients with SCD signifi-
cantly increased shortly after transition into adult care
[4]. The lack of specialists who are prepared to care for
this population has been postulated as a cause of poor
outcomes among these young adults [6]. Therefore,
there has been a movement to equip primary care pro-
viders to care for this patient population.
Obstetrician/gynecologists (OB/GYNs) play an import-
ant role in SCD screening and adult patient care through
their involvement with prenatal screening and pregnancy
management. Consequently, OB/GYNs should be aware
of the disease and basic principles of disease manage-
ment. There is a paucity of information on provider
knowledge and practice related to hemoglobinopathies
internationally and in the United States, but whatl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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knowledge regarding newborn screening and the signifi-
cance of trait status [7,8]. However, most of the available
literature focuses on provider knowledge regarding new-
born screening, not prenatal screening, and does not
specifically address obstetricians or provider knowledge
of disease management [9]. The purpose of this study
was to assess OB/GYN SCD-related screening and pre-
natal management practices as recommended by the




Eligible participants included Fellows and Junior Fellows of
the College. Six hundred of these physicians were selected
from the Collaborative Ambulatory Research Network
(CARN), which includes practicing College members who
volunteer to participate in research studies. Another 600
were selected from the general population of Fellows. Since
the management practice questions pertained to prenatal
care, we restricted our analysis to only those participants
who reported that they provide obstetric services.
Survey
The survey contained questions about the physicians’
demographics, training, practice characteristics and the
practice population. Regarding screening practices, par-
ticipants were asked about appropriate target groups for
prenatal sickle cell screening. Participants were asked the
recommended folic acid supplementation dose for this
population and about their SCD referral and consultation
practices. Additionally, participants were asked about
sources they used for information on blood disorders and
to rate their medical school and residency training experi-
ence regarding screening, assessment, and treatment of
sickle cell disease. The survey was mailed to participants
up to four times before they were considered a non-
respondent. The study was reviewed and approved by the
IRB at the American College of Obstetricians and Gyne-
cologists. The study was of minimal risk and participation
was voluntary. No identifying information was included in
the data file.
Statistical analysis
Statistical analysis was performed using SPSS version 16
(SPPS Inc., Chicago, IL, USA). Descriptive statistics such
as percentages, means, and standard deviations were used
to assess participant responses where appropriate.
Results
Of the 1,200 eligible participants, 15 could not be
reached and were excluded from the analysis. A total of
503 participants responded to the survey (overall responserate = 42.4%); 338 of these respondents were CARN mem-
bers (56.3% response rate) and 165 were non-CARN
members (27.5% response rate). Of the 503 responders,
382 provided obstetric services and were included in the
analyses. No significant differences in age, sex, number of
patients seen each week, number of patients seen each
year, number of deliveries, number of surgeries, percent
of patient races, primary care specialty, or residency of
patients were found between CARN and non-CARN re-
spondents; therefore the groups were combined for this
analysis.
Table 1 shows participant demographics and practice
characteristics. Fifty percent of participants were male.
On average, participants had been in practice 16.6 years
(standard deviation [SD] = 9.8) since residency. Fifty per-
cent practice in an OB/GYN partnership or group set-
ting. General OB/GYN was the reported primary medical
specialty for 91.1% of participants. Respondents most
frequently reported that their patients reside in urban,
inner-city areas (41.9%). The average percent of African-
American patients in each respondent’s practice was
14.5% (SD = 15.2%). The majority of participants (57.1%)
reported that they had not provided care to any patients
with SCD in the past year; however, of the 40.1% who had,
the majority had provided care to 1–5 patients. Most par-
ticipants reported that the College publications (82.7%)
and obstetric journals (67.8%) were important sources of
practice-relevant information regarding blood disorders.
Responses to questions regarding SCD screening and
knowledge were restricted to the 153 respondents that
reported seeing at least 1 patient with SCD in the last
year. Ninety-seven percent of these respondents reported
that they regularly screen people of African descent for
SCD or SCT, whereas 52.9% regularly screen people of
Mediterranean descent and 30.1% regularly screen people
of Asian descent (Table 2). If the mother screens positive
for SCD or SCT, 96.1% of respondents reported that
efforts are made to screen the partner. If both parents
screen positive for SCD or SCT, 89.5% of respondents
routinely refer them to a genetic counselor.
Respondents were most likely to consult with a maternal-
fetal medicine specialist (86.3%) or hematologist (83%) for
patients with SCD. Only 56.2% of the respondents who had
seen at least 1 patient with SCD in the last year knew the
recommended daily intake of folic acid for pregnant pa-
tients with SCD (Table 2).
Regarding medical school and residency training, very
few participants (0.3–2.1%) reported that their training on
sickle cell screening, assessment or treatment was nonex-
istent (Table 3). However, 19.6% reported that training on
SCD screening was barely adequate or inadequate, 28.5%
reported that training on assessment of SCD was barely
adequate or inadequate, and 39.3% reported that training
on treatment of SCD was barely adequate or inadequate.
Table 1 Participant and practice characteristics (n = 382)
Characteristic n Mean Percent
or SD*










Years in practice since residency (mean) — 16.6 SD = 9.8
Current practice
Solo practice 49 12.8
Health Maintenance Organization 8 2.1
OB/GYN partnership/group 191 50.0
University full-time faculty and practice 53 13.9
Multi-specialty group 53 13.9
Other 28 7.3
Primary medical specialty
General OB/GYN 348 91.1
Maternal-Fetal medicine 24 6.3
Obstetrics only 3 0.8
Reproductive endocrinology 1 0.3
Gynecology only 2 0.5
Other 4 1.0
Residence of patients
Urban, inner city 160 41.9
Suburban 118 30.9




Percent of patient race/ethnicity in
practice (mean)
Non-Hispanic White — 58.7 SD = 27.3
Hispanic — 17.5 SD = 21.3
African-American — 14.5 SD = 15.2
Native American — 1.7 SD = 8.0
Asian/Pacific Islander — 4.8 SD = 7.5
Other — 1.7 SD = 7.3
Table 1 Participant and practice characteristics (n = 382)
(Continued)
Patients seen each week (mean) — 89.4 SD = 41.0







21 or more 1 0.3
*Some columns do not total 100% because of missing responses.
SCD, sickle cell disease; SD, standard deviation.
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OB/GYNs are crucial to the care of women with SCD
for both prenatal screening and pregnancy management.
Prenatal screening of new mothers and their partners
can potentially identify people with the trait or the dis-
ease who would otherwise be missed by newborn screen-
ing, such as immigrants. Although improved management
practices have reduced the adverse outcomes associated
with pregnancy in women with SCD, there is still evidence
from population-based studies that these women continue
to be at increased risk of poor maternal and fetal out-
comes such as preeclampsia, infection, preterm labor, fetal
growth restriction, and fetal death [10-12]. As a conse-
quence of these risks, healthcare providers that encounterTable 2 Sickle cell disease (SCD) screening and
management practices (n = 153)*
n (%)†
Which of the following ethnic groups are
regularly screened as a part of prenatal care?‡
All 29 (19.0)
African descent§ 149 (97.4)
Mediterranean descent 81 (52.9)
Middle Eastern descent 58 (37.9)
Asian descent 46 (30.1)
Northern European descent 32 (20.9)
Other 38 (24.8)
What is the recommended daily folic acid intake
for pregnant patients with SCD?
1 mg 42 (27.5)
2 mg 20 (13.1)
4 mg 86 (56.2)
6 mg 3 (2.0)
*Responses were restricted to only participants who provide obstetric services.
†Some columns do not total 100% because respondents were asked to check
all that apply or because of missing responses.
‡Those who indicated “All” were included in totals for the individual ethnic groups.
§Responses in bold indicate correct responses for SCD, sickle cell disease.
Table 3 Description of sickle cell disease-related medical school and residency training (n = 382)
n (%)*
Comprehensive Adequate Barely adequate Inadequate Nonexistent
SCD screening 73 (19.1) 232 (60.7) 56 (14.7) 19 (5.0) 1 (0.3)
SCD assessment 55 (14.4) 212 (55.5) 83 (21.7) 26 (6.8) 5 (1.3)
SCD treatment 39 (10.2) 183 (47.9) 97 (25.4) 53 (13.9) 8 (2.1)
*Some responses do not total 100% because respondents did not provide an answer.
SCD, sickle cell disease.
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SCD and its management in order to provide appropriate
care for this population [13,14].
Nonetheless, most studies regarding provider knowledge
of SCD have focused on assessing knowledge of newborn
screening, which many prenatal care providers believe falls
under the purview of pediatricians [15,16]. To our know-
ledge, this is the first study to assess the knowledge of
sickle cell disease prenatal screening and related practice
patterns among OB/GYNs.
The College has established guidelines for the manage-
ment of hemoglobinopathies in pregnancy, which specify
that women of African, Mediterranean, and Southeast
Asian descent should be screened for hemoglobinopa-
thies; that if found to be carriers, these women should
be referred to genetic counseling; and that women with
SCD should be prescribed 4 mg of folate supplementation
daily [17]. In spite of this, we observed that while 97.4% of
respondents regularly screened people of African descent,
only 52.9% regularly screened people of Mediterranean
descent, and 30.1% regularly screened people of Asian
descent. Additionally, only 56.2% of respondents knew the
correct amount of folate to prescribe to pregnant women
with SCD. The College also recommends that couples at
risk of having a child with a hemoglobinopathy be referred
to a genetic counselor for a review of prenatal testing and
reproductive options. We observed that 89.5% of respon-
dents reported that they routinely referred couples to gen-
etic counseling if both screened positive for SCT. This
limited knowledge of SCD was consistent with the find-
ings of a study of family health practitioners in Brazil, in
which less than 75% correctly answered knowledge ques-
tions regarding SCD epidemiology, clinical manifestations
and management [18].
The reason for the poor compliance with the College
guidelines is unclear, considering that 82.7% of respondents
reported that the College publications were an important
source of information on blood disorders.
However, given that 19.6% to 39.3% of respondents
believed training on SCD screening, assessment and treat-
ment was barely adequate or inadequate, there may be an
opportunity to enhance this knowledge via more robust
training and medical education on SCD. There is evidence
that interventions to increase provider knowledge regarding
SCD can be effective [19]. Oyeku et al. [20] demonstratedthat simple education strategies such as mailed materials or
interactive seminars can increase provider knowledge of
SCD newborn screening result management and increase
provider confidence in providing newborn screening
follow-up care. Our study suggests that an option for
educating practicing OB/GYNs on SCD would be through
publication of educational materials in OB/GYN specialty
organization publications.
Our study was limited by several factors. CARN mem-
bers, a group of physicians predisposed to participate in
research studies, comprised the majority of respondents.
The response rate of 42% was relatively low, but while
this rate is comparable to other studies that included mem-
bers of CARN [21,22], it may have introduced responder
bias and limited generalizability of the finding. Unfortu-
nately, demographic information on non-respondents was
not readily available for comparison, so the representative-
ness of the respondent sample could not be assessed. Also,
the screening and management practice questions were re-
stricted to the relatively small number of respondents who
had provided care to 1 or more patients with SCD in the
previous year. This could lead to bias in that providers who
have seen patients with SCD may be primed to perform
prenatal screening; therefore, these findings may have been
an overestimation of the quality of management practices
of the general population of OB/GYNs. Finally, since prac-
tice behaviors were assessed by self report, our assessment
of these behaviors may have been subjective.
Conclusions
In order to ensure appropriate delivery of healthcare for
pregnant patients with sickle cell disease, it is of utmost
importance that providers have a fundamental understand-
ing of the disease and are aware of relevant professional
management guidelines. Our study demonstrates a discon-
nect between the published College Guidelines on both
appropriate target populations for prenatal SCD screening
and recommendations for folic acid supplementation and
the practice behaviors of OB/GYNs. If at-risk women and
their partners are not screened, it is a missed opportunity
to provide education and intervene when appropriate.
Future efforts should focus on enhancing undergraduate
and graduate medical education and disseminating infor-
mation about SCD to practicing physicians through suit-
able channels.
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aThe American College of Obstetricians and Gynecolo-
gists (the College) is a professional association of physicians
specializing in obstetrics and gynecology. In order to be-
come a Fellow or Junior Fellow, a board certified ob-gyn,
whose professional activity is devoted to the practice of ob-
stetrics and/or gynecology, needs to apply and be approved
for Fellowship.
bThe Collaborative Ambulatory Research Network is
comprised of a group of practicing ACOG Fellows, who
voluntarily participate in survey research on ambulatory
care issues affecting Fellows of ACOG and their patients.
Information from the studies is used to develop better
informed educational strategies, and to disseminate in-
formation to physicians in those areas in which a know-
ledge deficit is apparent. Funding is provided by the
cooperative agreement grant, UA6MC19010, through the
U.S. Department of Health and Human Services, Health
Resources and Services Administration, Maternal and
Child Health Research Program.
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